Nilotinib and dasatinib-new 'magic bullets' for CML?

被引：3

作者：

Breccia, Massimo ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2010年 / 7卷 / 10期

关键词：

CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; IMATINIB; MG;

D O I：

10.1038/nrclinonc.2010.151

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The efficacy of nilotinib and dasatinib as frontline treatment of chronic myeloid leukemia has been documented in small phase II studies. Now, two clinical trials have assessed the effectiveness of second-generation tyrosine kinase inhibitors in comparison with standard dose imatinib at 1 year. Will these results change our current practice?

引用

页码：557 / 558

页数：3

共 10 条

[1]

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[2]

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study [J].

Cortes, Jorge E. ;

Baccarani, Michele ;

Guilhot, Francois ;

Druker, Brian J. ;

Branford, Susan ;

Kim, Dong-Wook ;

Pane, Fabrizio ;

Pasquini, Ricardo ;

Goldberg, Stuart L. ;

Kalaycio, Matt ;

Moiraghi, Beatriz ;

Rowe, Jacob M. ;

Tothova, Elena ;

De Souza, Carmino ;

Rudoltz, Marc ;

Yu, Richard ;

Krahnke, Tillmann ;

Kantarjian, Hagop M. ;

Radich, Jerald P. ;

Hughes, Timothy P. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :424-430

[3]

Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia [J].

Cortes, Jorge E. ;

Jones, Dan ;

O'Brien, Susan ;

Jabbour, Elias ;

Ravandi, Farhad ;

Koller, Charles ;

Borthakur, Gautam ;

Walker, Brenda ;

Zhao, Weiqiang ;

Shan, Jianqin ;

Kantarjian, Hagop .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :398-404

[4]

DELNINGER M, 2009, BLOOD, V114, pA1126

[5]

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [J].

Kantarjian, Hagop ;

Shah, Neil P. ;

Hochhaus, Andreas ;

Cortes, Jorge ;

Shah, Sandip ;

Ayala, Manuel ;

Moiraghi, Beatriz ;

Shen, Zhixiang ;

Mayer, Jiri ;

Pasquini, Ricardo ;

Nakamae, Hirohisa ;

Huguet, Francoise ;

Boque, Concepcion ;

Chuah, Charles ;

Bleickardt, Eric ;

Bradley-Garelik, M. Brigid ;

Zhu, Chao ;

Szatrowski, Ted ;

Shapiro, David ;

Baccarani, Michele .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) :2260-2270

[6]

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance [J].

Kantarjian, Hagop M. ;

Giles, Francis ;

Gattermann, Norbert ;

Bhalla, Kapil ;

Alimena, Giuliana ;

Palandri, Francesca ;

Ossenkoppele, Gert J. ;

Nicolini, Franck-Emmanuel ;

O'Brien, Stephen G. ;

Litzow, Mark ;

Bhatia, Ravi ;

Cervantes, Francisco ;

Haque, Ariful ;

Shou, Yaping ;

Resta, Debra J. ;

Weitzman, Aaron ;

Hochhaus, Andreas ;

le Coutre, Philipp .

BLOOD, 2007, 110 (10) :3540-3546

[7]

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor [J].

Marin, David ;

Milojkovic, Dragana ;

Olavarria, Eduardo ;

Khorashad, Jamshid S. ;

de lavallade, Hugues ;

Reid, Alistair G. ;

Foroni, Letizia ;

Rezvani, Katayoun ;

Bua, Marco ;

Dazzi, Francesco ;

Pavlu, Jiri ;

Klammer, Matthias ;

Kaeda, Jaspal S. ;

Goldman, John M. ;

Apperley, Jane F. .

BLOOD, 2008, 112 (12) :4437-4444

[8]

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia [J].

Rosti, Gianantonio ;

Palandri, Francesca ;

Castagnetti, Fausto ;

Breccia, Massimo ;

Levato, Luciano ;

Gugliotta, Gabriele ;

Capucci, Adele ;

Cedrone, Michele ;

Fava, Carmen ;

Intermesoli, Tamara ;

Cambrin, Giovanna Rege ;

Stagno, Fabio ;

Tiribelli, Mario ;

Amabile, Marilina ;

Luatti, Simona ;

Poerio, Angela ;

Soverini, Simona ;

Testoni, Nicoletta ;

Martinelli, Giovanni ;

Alimena, Giuliana ;

Pane, Fabrizio ;

Saglio, Giuseppe ;

Baccarani, Michele .

BLOOD, 2009, 114 (24) :4933-4938

[9]

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia [J].

Saglio, Giuseppe ;

Kim, Dong-Wook ;

Issaragrisil, Surapol ;

le Coutre, Philipp ;

Etienne, Gabriel ;

Lobo, Clarisse ;

Pasquini, Ricardo ;

Clark, Richard E. ;

Hochhaus, Andreas ;

Hughes, Timothy P. ;

Gallagher, Neil ;

Hoenekopp, Albert ;

Dong, Mei ;

Haque, Ariful ;

Larson, Richard A. ;

Kantarjian, Hagop M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) :2251-2259

[10]

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia [J].

Shah, Neil P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Rea, Delphine ;

Dorlhiac-Llacer, Pedro E. ;

Milone, Jorge H. ;

Vela-Ojeda, Jorge ;

Silver, Richard T. ;

Khoury, H. Jean ;

Charbonnier, Aude ;

Khoroshko, Nina ;

Paquette, Ronald L. ;

Deininger, Michael ;

Collins, Robert H. ;

Otero, Irma ;

Hughes, Timothy ;

Bleickardt, Eric ;

Strauss, Lewis ;

Francis, Stephen ;

Hochhaus, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) :3204-3212

← 1 →